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Introduction
The 9th International AIDS Society Conference on HIV Science
(IAS 2017) took place at the Palais des Congrès, in Paris, France,
from 23 to 26 July 2017, chaired by Linda-Gail Bekker and
Jean-François Delfraissy. It was organised by the International AIDS
Society (IAS) in partnership with ANRS (the French national agency
for research on AIDS and viral hepatitis), bringing together more
than 6000 leading scientists, researchers and HIV professionals
from around the world. The Conference featured more than 1800
abstracts selected for oral and poster presentations out of over
4300 submissions, in addition to plenary sessions and satellite
symposia.
Prevention was high on the agenda of this year‘s Conference. Data
relevant to children, adolescents and adults with HIV on recent
advances in the understanding of viral–host interactions, targeting
of the HIV reservoir, new oral and long-acting antiretroviral drugs,
strategies for simplification of treatment regimens, immune-based
therapies, pre-exposure prophylaxis (PrEP) to HIV, prevention of
mother-to-child transmission, prophylactic and therapeutic
vaccines, as well as comorbidities including hepatitis, were
presented with an emphasis on translating science into practice
and policies.
HIV prevention
In a satellite symposium around systemic pre-exposure prophylaxis
(PrEP) organised by the HPTN/FHI 360, Myron Cohen (University
of North Carolina School of Medicine, USA) gave an overview of
the field. He discussed the combination of four preventative
methods, namely behavioural to avoid exposure, precoital/coital
and postcoital to decrease the effect of potential transmission,
and treatment as prevention (TasP) in order to reduce infectivity
of people living with HIV (PLWH). The challenge of sustained
adherence to a daily PrEP regimen such as oral Truvada and the
need to develop new agents such as long-acting (LA) injectable
formulations, broadly neutralising antibodies (bNAbs) and
antiretroviral (ARV) implants were also considererd.
The case for HIV prevention using monoclonal antibodies
(mAbs) was presented by Nyradzo Mgodi (University of
Zimbabwe)(MOSA0203). The AMP (antibody-mediated
prevention) study is a Phase 2b trial that is under way and includes
two harmonised proof-of-concept trials. It will evaluate the efficacy
of the VRC01 bNAb that targets the CD4 binding site of the HIV-1
envelope protein among high-risk populations in 47 sites and 11
countries. VRC01 neutralises 90% of 190 strains tested. It is the
first mAb to enter into advanced human clinical testing for
prevention. Questions remain over whether it can provide
protection from infection with adequate levels of mAb and if
antibody-dependent cell-mediated cytotoxicity (ADCC) is needed
for efficacy. The combination of VRC01 with a next-generation
neutralising antibody, VRC07-523 LS, is likely to improve the
potency and breadth of protection in humans.
Thomas Hope (Northwestern University, USA) presented the next
generation drug and delivery modalities for PrEP (MOSA0204),
namely sustained LA protection against HIV (SLAP-HIV). SLAP-HIV
includes injectable formulations as well as biodegradable and
removable implants. It remains to be shown whether these have
an efficacy comparable to oral and systemic PrEP versus topical
PrEP such as microbicides, and whether prevention of HIV
acquisition also occurs at the cellular level. In a small study
conducted in nine pigtail macaques that were vaginally challenged
with SIVmac239, immunostaining and fluorescent microscopy
revealed that smaller foci of infected cells were observed in animals
treated with oral PrEP compared to topical PrEP, such as with an
intravaginal ring. Indeed, in terms of herd immunity, systemic PrEP
can prevent systemic infection even if the drug coverage is
suboptimal.
Connie Celum (University of Washington, Seattle, USA) analysed
how to optimise oral PrEP delivery (MOSA0205). PrEP is a safe
and effective preventative option; however, stigma, and lack of
knowledge and access, are key barriers to its use. Young African
women are particularly at risk of HIV infection, representing over
one-third of new HIV infections. Several studies are under way
to try to understand PrEP uptake and adherence issues in these
women in order to develop effective messaging, easier delivery
options and interventions, and to maximise adherence, by using
interventions such as peer support and open discussions. She
concluded by suggesting a personalised PrEP approach to provide
positive and engaging messaging, as well as simple delivery
procedures.
During one of the plenary sessions Sheena McCormack (MRC,
London, UK) (TUAC0101) presented in her talk ‘Adding D to the
ABC: Putting the Drugs in the ABC of Prevention’ updated results
of the PROUD study long-term follow-up through to November
2016. These data showed that the benefit of such intervention
was sustained with high PrEP persistence [1]. In this study men
who have sex with men (MSM) (n=544) attending sexual health
clinics in the UK were randomised to receive daily tenofovir/
emtricitabine (TDF/FTC), either immediately (IMM), or after a
12-month deferral period (DEF). PROUD was initiated after clinical
trials that first established that TDF/FTC PrEP was efficacious for
HIV prevention, but questions remained about what its
effectiveness might be in real-world settings. The main efficacy
outcomes were based on the DEF phase, when IMM, but not the
DEF participants, had access to PrEP. It was shown in this trial
that PrEP reduced HIV incidence by 86% among those assigned
to IMM use. In the DEF group, 206 of 269 eventually started PrEP
and about two-thirds were still taking PrEP at the end of the
*Corresponding author: Christina K Psomas, Department of Infectious
Diseases, University Hospital of Montpellier, 80 A Fiche Avenue,
34295 Montpellier Cedex 5, France
Email: c-psomas@chu-montpellier.fr
Journal of Virus Eradication 2017; 3: 242–249CONFERENCE REPORT
© 2017 The Authors. Journal of Virus Eradication published by Mediscript Ltd
This is an open access article published under the terms of a Creative Commons License.242
follow-up, which was, for some, 3 years after starting in the trial.
Since November 2016 all participants have been offered PrEP and
the trial has entered into the post-DEF phase. Investigators have
compared HIV incidence rates and selective sexually transmitted
infections (STIs) during the DEF and post-DEF phases. There was
no difference in terms of HIV incidence between groups in the
post-DEF phase (P=0.18), but a decreased incidence was noted
in the DEF participants once they had had access to PrEP
(P<0.0001). The rate of HIV acquisition in the IMM group
remained similar during the two trial phases (P=0.66). Three years
after PrEP initiation, reduction in HIV incidence was sustained,
thereby confirming high adherence and durable effectiveness of
PrEP in this population. The most likely reason for new HIV
infections was the lack of PrEP intake at the time of exposure.
The incidence of rectal STI infections was high in both groups and
trial phases.
The MWRI-01 trial, headed by Ian McGowan (University of
Pittsburgh, USA) (TUAC0103) aimed to evaluate the safety and
acceptability of long-acting (LA) rilpivirine (RPV) given as an
intramuscular (IM) injection, with exploratory analyses of HIV
infection in cervical, vaginal and rectal explants after exposure
to the compound [2,3]. Three 1200-mg IM doses of LA RPV were
shown to be safe and acceptable. Mild-to-moderate injection site
pain was the most common adverse event reported. In the rectal
explant, inhibition of both subtype B and C virus persisted up to
4 months after the last injection and for 2 months in the cervical
explant after the first injection.
Katherine Bunge (University of Pittsburgh, USA) presented the
results of a Phase 2a trial in US adolescents of a 25-mg dapivirine
(DAP) vaginal ring or placebo inserted every 4 weeks for 24 weeks
(MTN-023/IPM-030) [4]. There had been no protection in the
two previous double-blind placebo-controlled trials in 18–21-
year-old participants because of poor adherence [5,6]. In this new
trial, it was shown to be safe and acceptable in this population
(15–17-year-olds) from six US cities in a 96-person (randomisation
3:1) placebo-controlled trial, and a high level of adherence was
found when testing for plasma DAP levels and residual drug levels
in used rings.
Sharon Hillier (University of Pittsburgh, USA), presented data
evaluating whether vaginal microbiota associated with bacterial
vaginosis impacted on dapivirine concentrations in the genital tract
tissues and plasma following vaginal application [7]. There was
no association found between increasing vaginal concentrations
of Gardnerella vaginalis as detected by qPCR and dapivirine (DAP)
concentrations in cervical tissue or plasma (P=0.93 and 0.99,
respectively), this is in contrast to tenofovir, suggesting that DAP
levels following vaginal application are not impacted by the
microbiota associated with bacterial vaginosis.
Raphael Landovitz (Center for Clinical AIDS Research and
Education, USA) presented results from the HPTN 077 study
regarding safety, tolerability and pharmacokinetics of injectable
long-acting cabotegravir (CAB LA) in low-risk HIV-uninfected
women and men [8]. This study is a multi-site, double-blind,
randomised (3:1), placebo-controlled trial including two ongoing
cohorts (2×400-mg IM injections every 12 weeks or 1×600-mg
IM injection every 8 weeks) in a total of 199 participants, aged
18–65 years, at eight sites in Brazil, South Africa, Malawi and the
USA. The CAB LA was well-tolerated at doses of 800 mg (2×2 mL)
and 600 mg (1×3 mL) in HIV-uninfected and low-risk males and
females. Injection site reactions (ISR) were frequent but generally
mild with only one (0.75%) participant discontinuing injections.
The 600-mg IM every 8 weeks dosing schedule, after a 4-week
loading dose, consistently met pre-specified pharmacokinetic (PK)
targets in both sexes and is being evaluated in Phase 3 efficacy
studies in at-risk individuals.
The session on the ‘Next Wave of Prevention Options’ (SUSA15)
offered an update on the future pipeline of products. Alex Rinehart
(ViiV Healthcare, USA) gave an update on prevention with the
injectable CAB LA (SUSA1502). Preclinical and clinical data support
its use for HIV treatment and prevention (HPTN 083 and HPTN
084 Phase 3 trials, in MSM/TGW and women, respectively, using
CAB LA at 600 mg). Challenges remain, such as the date of the
trial end, which is dependent on the background incidence and
seroconversion rates, how to manage the ‘PK tail’, and the
potential for resistance development.
Kenneth Mayer (Fenway Institute, USA) evaluated the community
perceptions on HIV prevention options (SUSA1504). Among 4638
MSM, who responded to an online survey, a large majority (78%)
had heard of PrEP, but only 15% had ever used it. Interest in other
PrEP modalities was high, with a preference for antibody infusion
and injectable ARVs rather than the topical rectal approach.
Antiretroviral therapy
New drugs and formulations were described in several trials as
well as new ways to use current drugs, including treatment
simplification and novel dosing.
The large focus on a new agent was for the single-tablet regimen
(STR) of the new integrase inhibitor, bictegravir (BIC) 50 mg
combined with tenofovir alafenamide (TAF) 25 mg and
emtricitabine (FTC) 200 mg, with data presented from two trials
(GS-1489/1490). The first, presented by Joel Gallant (Southwest
CARE Centre, USA), a Phase 3, placebo-controlled study, compared
BIC/FTC/TAF to Triumeq (dolutegravir/abacavir/lamivudine –
DTG/ABC/3TC) and showed non-inferiority of the investigational
combination drug [9].This study took place in North America and
Europe and randomised (1:1) 629 subjects, with a median age
of around 31 years. The subjects were 90% male and 36% were
of black ethnicity. Entry requirements to the study included an
eGFR above 50 mL/min, to be HLA-B*5701 negative and not to
have any resistance mutations. Around 16–17% in both study arms
had a viral load (VL) above 100,000 HIV-1 copies/mL at baseline.
Overall both arms performed well, with a 92.4% suppression rate
(<50 HIV-1 copies/mL) at 48 weeks in the BIC/FTC/TAF arm
compared to 93.0% in the DTG/ABC/3TC arm, confirming BIC STR
non-inferiority. Nausea was more frequently reported in the
DTG-based arm (22.9% vs 10.2%; P<0.001) but both drugs were
otherwise well tolerated. In the small (five subjects) number of
virological failures (VF) above 200 HIV-1 copies/mL, there were
no identified resistance mutations to any component drug. No
discontinuations due to adverse events (AEs) occurred in the BIC
arm. Four occurred in the DTG arm and were considered to be
related to the study drug (nausea, thrombocytopenia, chronic
pancreatitis/steatorrhoea, depression). The lipid, bone and renal
parameters were comparable in both groups.
The second Phase 3 study (GS-1490) was presented by Paul Sax
(Brigham and Women‘s Hospital, USA) in a Late Breaker session
and compared BIC/TAF/FTC to DTG/TAF/FTC [10]. It was
placebo-controlled with a 1:1 randomisation and 625 randomised
participants. In the DTG arm 93% of participants met the primary
endpoint of a VL<50 HIV-1 copies/mL at 48 weeks compared to
89% in the BIC arm. The non-inferiority criteria were met with
no resistance observed in the failures in either arm. Eleven
participants discontinued BIC compared to three receiving DTG.
No difference in side effects, including nausea, was noted.
Doravirine (DOR) is a non-nucleoside reverse transcriptase inhibitor
(NNRTI), which can be used in the context of a background of
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NNRTI mutations, including K103N. It has previously been shown
to be non-inferior to ritonavir-boosted darunavir (DRV/r) in the
Phase 3 DRIVE-Forward study [11]. Data from the DRIVE-AHEAD
study were presented at the Conference [12], a placebo-controlled
Phase 3 study comparing the STR of DOR/tenofovir disoproxil
fumarate (TDF)/3TC with Atripla (efavirenz [EFV]/TDF/3TC). The
primary end point was the proportion of people with HIV-1 RNA
below 50 HIV-1 copies/mL at 48 weeks. There were approximately
730 participants randomised in a 1:1 allocation, with 85% male
participants and a median age of 31 years. The mean baseline CD4
cell count was approximately 420 cells/mm3, about 22% had a
VL >100,000 HIV-1 copies/mL and 14% had a history of AIDS.
Eighty-six percent of participants continued DOR at 48 weeks,
compared to 83% in the EFV arm. Non-inferiority criteria were
met with 84% of the DOR arm having <50 HIV-1 copies/mL at
week 48, compared to 81% in the EFV arm. Resistance to NNRTIs
emerged in 1.6% participants on DOR, and 3.3% on EFV. Half
as many people in the DOR arm experienced drug-related AEs
(31% vs 63%) but serious AEs were rare in both arms (<1%). The
most common AEs in the DOR arm were headache (13%) and
diarrhoea (11%). Skin rash was less common with DOR (5% vs
12%). However, DOR caused significantly fewer CNS side effects.
Discontinuation rates in the EFV arm were higher, with dizziness,
rash and abnormal dreams occurring more frequently. Lipid changes
were more favourable on DOR/3TC/TDF, with better fasting
low-density lipoprotein (LDL) and non-high-density lipoprotein
(non-HDL) levels.
New antiretroviral routes
While modern oral ARV agents are generally well tolerated,
adherence to a daily pill regimen remains challenging for some
individuals, creating a need for alternatives. The 96-week results
of the LATTE-2 study [13,14] were presented. In this study,
following an oral induction phase, subjects either received IM
injections of CAB and RPV, 4 or 8 weeks apart, or continued on
oral triple therapy (ABC/3TC/CAB). Around 90% of participants
maintained an undetectable VL (<50 HIV-1 copies/mL) over 2
years. Injection site reactions were common, but usually mild to
moderate and transient, with subjects reporting overall high
satisfaction. It is worth noting, however, that two participants (2%)
in the 8-week group, eight (7%) in the 4-week group, and one
(2%) in the oral group discontinued treatment because of AEs.
New ways to use antiretrovirals
ANDES is a study evaluating a generic fixed-dose combination
of boosted darunavir (FD-DRV/r) plus 3TC versus FD-DRV/r plus
TDF/3TC in ARV-naive subjects in Argentina. The primary study
outcome was the proportion of participants in each study arm with
a VL <50 HIV-1 copies/mL at week 48. Participants had a median
age of 30 years, 91% were male, median baseline VL was 32,000
HIV-1 copies/mL and CD4 T cell count was 383 cells/mm3. About
25% in each group had a VL at baseline >100,000 HIV-1 copies/
mL. The data presented were of the 24-week analysis [15].
Seventy-five participants were randomised to the dual arm and
70 to the triple therapy, with 90% of them being male. Four people
in the dual-therapy group stopped treatment and one dropped
out of the triple-therapy arm. The primary end point at 24 weeks
was met in 97% in the triple-therapy arm versus 95% in the
dual-therapy arm (difference −2.5%, 95% CI −7.0–2.9). Non-
inferiority was achieved and side effects were fewer in the
dual-agent arm (22.9% vs 13.3%). Gastrointestinal and
neurological complaints were seen more often in the triple therapy
arm. Rash was present in 8% and 7.1% in the dual- and triple-
therapy arms, respectively. The study will continue through 48
weeks.
In the MOBIDIP trial, dual therapy with boosted protease inhibitors
(bPI) plus 3TC showed superiority to bPI monotherapy in
maintaining virologically controlled patients on second-line ART
at 48 weeks leading to the discontinuation of the monotherapy
arm [16]. Data presented in Paris included the continuation of
the dual therapy arm up to week 96 [17]. The trial was conducted
in three countries in sub-Saharan Africa with 70% of the 132
patients in the dual arm being female. The bPI was darunavir in
one-third of participants or lopinavir in two-thirds. Importantly,
among those with first-line VF, 97% had an M184V mutation. At
96 weeks, in an intention-to-treat (ITT) analysis, 8.3% of
participants failed in the dual arm (eight virological failures, one
death, two lost to follow-up). In three patients, in which TDF had
been reintroduced, a VL <200 HIV-1 copies/mL was achieved in
a median of 13 weeks. The authors concluded that after viral
suppression with bPI plus NRTIs in second-line therapy,
maintenance with bPI plus lamivudine was associated with a high
rate of long-term success, despite the presence of an M184V
mutation. None of those whose treatment had failed developed
any new mutations and there was no presumed impact on
subsequent treatment options.
Dual therapy: integrase inhibitor plus nucleoside
reverse transcriptase inhibitors
The ACTG A5353 pilot study evaluated dual therapy in ART-naive
individuals as a single-arm study, with all participants receiving
DTG/3TC [18]. At 24 weeks 108/120 (90%) participants had a
viral load <50 HIV-1 copies/mL. All three virological failures were
due to poor adherence and low drug levels. The study aimed to
look at this combination in people with high VL and included
participants with baseline VL up to 500,000 HIV-1 copies/mL. A
previous study with the same treatment combination, PADDLE,
had excluded those with a VL >100,000 HIV-1 copies/mL [19].
In the present study, 37 (31%) participants had a VL >100,000
HIV-1 copies/mL. Resistance testing detected an integrase
mutation (R263RK) and a reverse transcriptase (RT) mutation
(M184V) in one participant with VF. No participant stopped study
drugs because of AEs.
While these data are reassuring, the two large randomised trials
of DTG/3TC versus DTG/TDF/FTC (GEMINI-1 and GEMINI-2) are
still ongoing and should provide further information regarding this
type of combination as a first-line treatment.
Dual therapy: integrase inhibitor with nucleoside
sparing
Safety data were presented from the SWORD studies showing that
switching from TDF/FTC-based triple therapy (combined
antiretrovirals; CAR) to the combination of DTG/RPV resulted in
a significant improvement in bone markers [20]. A sub-study of
the international, multicentre SWORD 1 and 2 studies looked at
bone mineral density (BMD) using DEXA scanning with the primary
end point being the percentage change in total hip BMD. At week
48 the DTG/RPV patients had an increase in hip bone density
from baseline (1.34%), which differed from CAR patients (P=0.01),
serological bone markers also showing improvement.
New frontiers: integrase inhibitors and resistance
An interim week-24 analysis of DAWNING, an international,
multicentre, non-inferiority study, was presented during the Late
Breaker session [21]. Its aim was to compare DTG/2 NRTIs to
ritonavir-boosted lopinavir (LPV/r) during second-line therapy in
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participants who had previously failed NNRTI-based first-line ART.
The study was mainly conducted in resource-limited settings. It
was an open-label, randomised trial in which the LPV/r arm had
been stopped early. There were 624 participants randomised, of
whom over 30% were female. At week 24 of the study the DTG
arm had been found to be superior to the LPV/r arm (P<0.001).
This effect was maintained at week 36 and week 48 with full results
awaited. Drug-related AEs were lower in the DTG arm (2%
discontinued DTG compared to 5% LPV/r). Central nervous system
(CNS) events were similar in both arms.
Low failure rate with switch to integrase
inhibitor STR despite archived mutations
A very low failure rate was found in this French retrospective study
in which subjects who were virologically suppressed for a prolonged
period of time switched for toxicity or simplification reasons to
an elvitegravir or dolutegravir-based STR [22]. Participants, who
had previously had a well-controlled VL (≤50 copies/mL at
baseline) were switched to elvitegravir/cobicistat/tenofovir/
emtricitabine or to dolutegravir/abacavir/lamivudine from two
nucleos(t)ides plus an NNRTI (35%), a PI (36%), or an integrase
inhibitor (17%), or from a different regimen (12%). Fifty-one
(68%) of the 75 individuals enrolled had a previous genotype with
22 (32%) displaying one or more reverse transcriptase (RT)
mutations. The M184V mutation (88%) was by far the most
frequently detected. Median follow-up was 13 months. One (2%)
participant in the genotyped group and none in the non-
genotyped group had VF. These data indicate that an integrase
inhibitor-based STR can generally maintain virological suppression
in people with long ART experience, including in those with a
record of archived RT or integrase mutation.
New formulations
The Phase 3 EMERALD study data were presented regarding a
co-formulated, single daily tablet, consisting of darunavir,
cobicistat, emtricitabine and tenofovir alafenamide (10mg)
(D/C/F/TAF) [23]. Suppressed subjects were randomised to either
receive D/C/F/TAF or remain on TDF/FTC plus a ritonavir-boosted
PI. In total, 1141 patients were randomly allocated with 763 in
the D/C/F/TAF arm versus 378 in the control arm. The non-
inferiority criteria were met with comparable AEs in both arms.
Some improvement in renal markers was noted, consistent with
the TAF component, in the D/C/F/TAF arm.
New dosing: efavirenz 400mg
In a Late Breaker poster discussion Marta Boffito (Chelsea and
Westminster Hospital, London, UK) presented data on low-dose
EFV at 400 mg (EFV400) during pregnancy and postpartum [24].
ARV dose reduction may translate into greater benefits for more
individuals. ENCORE-1 had shown no difference between EFV
dosed at 600 mg and at 400 mg. The WHO clinical guidelines now
recommend it as an alternative first-line agent with a disclaimer
because of the absence of data on its use during the third trimester
of pregnancy (TT). This study investigated its PK, efficacy and
CYP2B6 pharmacogenetics in women living with HIV (WLWH)
during the TT and postpartum (PP) in an open-label, multicentre
study performed in the UK and Uganda. Twenty-two females of
African origin with an undetectable VL were enrolled and switched
from a stable regimen of TDF/FTC/EFV 600 mg to TDF/FTC/EFV
400 mg. Weekly therapeutic drug monitoring was performed 10–14
hours post-dosing and a bi-weekly VL was measured. Undetectable
VL was maintained throughout the study with only two viral blips
observed and later confirmed as <50 HIV-1 copies/mL when
repeated. No WLWH were excluded from the study because of
low EFV TDM levels. No children born were infected with HIV.
Drug levels, Cmax, AUC and C24h were lower in the third trimester
than in non-pregnant women, but within the therapeutic range
for EFV dosed at 600 mg. The drug was well tolerated with no
grade 3 or 4 AEs. The conclusion was that EFV 400 mg may be
safely considered in pregnant women.
Primary HIV infection and early ART treatment
The session included presentations on clinical, immunological and
virological aspects of acute/primary HIV infection (PHI). Christine
Rouzioux (Necker Hospital, Paris, France) (TUBS0102) emphasised
the association between early/immediate treatment of HIV-1 and
reduced reservoirs in blood, gut, lymphoid cells and semen. The
timing of ART initiation has been shown to have an important
impact on several aspects of the infection. Subjects treated during
PHI display major differences in their HIV reservoir compared to
those who have initiated treatment during the chronic phase (CHI),
with a lower HIV DNA level. The T cell subset distribution of HIV-1
DNA also differs between PHI and CHI, the long-lived HIV reservoir
in CHI patients being composed of central memory T cells (TCM)
[25] while PHI patients have a short-lived reservoir of transitional
CD4 T cells (TTM) [26]. Additionally, PHI patients show an improved
level of CD4 T cell immune restoration [27]. The majority of early
treatment studies have included participants at Fiebig stage 4 or
5, but, as shown, even days matter at this stage of the infection.
Early ART limits the HIV reservoir seeding by restricting the VL
burden before it reaches its peak, thereby preserving potent
effector CD8 T cells. In terms of immune responses, we have to
distinguish between the various Fiebig stages as the degree of
immune impairment depends on the delay in treatment initiation
after infection.
Lydie Trautman (Walter Reed Army Institute of Research, US Army,
USA) (TUBS0103) presented data on B cell and T follicular helper
cells (Tfh) immune dysfunction, which is better detected at Fiebig
stage 3 than at stage 1–2. Very early ART results in the
preservation of the B cell resting memory compartment, thereby
preventing the impairment of circulating Tfh-dependent humoral
responses and maintaining the HIV-specific CD8 T compartment
with an enhanced memory potential.
However, it is now obvious that early treatment is still not enough
to preserve a fully functional immune system and additional
interventions are considered at this very early stage of the
infection, such as therapeutic vaccines, neutralising antibodies,
latency-reversing agents, or a combination of such interventions,
in the hope of achieving a more rapid VL reduction, thereby
potentially enabling a later VL control without daily medication
as discussed by Jintanat Ananworanich (Military HIV Research
Program, US Military, USA) (TUBS0106). John Frater (Oxford
University, UK) (TUBS0104) emphasised the need to start treating
patients as soon as possible during PHI in order to potentially
improve long-term clinical disease outcome.
HIV eradication
The HIV reservoir remains a lasting hurdle in the search for HIV
eradication and cure. New assays are being explored to achieve
enhanced characterisation and quantification. Christine Fennessey
et al. have generated a viral model to help the understanding of
the mechanisms of persistence [28] in which rhesus macaques were
infected withal a SIVmac239 virus tagged with a barcode
(SIVmac239M). Using next-generation sequencing, viral clonotypes
were identified in the original virus stock and plasma before and
after ART. Only five distinct barcode variants were detected in the
post-ART during peak VL out of a total of 250–2900 distinct viral
clones present during the pre-ART period. In some cases, a few
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rebound clones could not be detected in the pre-ART analysis.
Since all clones virologically had a similar replicative capacity, these
rebounding clones were representative of the reactivation kinetics.
The SIVmac239M virus therefore allows assessment of the efficacy
of reservoir-targeting interventions, based on the number and
dynamics of rebounding variants, even if time to measurable VL
remains unaffected.
Elisabeth Anderson (National Cancer Institute, Frederick, USA)
described a method to investigate how the proviral landscape
changes under ART [29]. HIV DNA was quantified by targeting
an internal HIV DNA sequence, such as gag, considered
representative of the full length proviral sequences and LTR of
all sequences, including those proviral sequences containing
deletions and/or defective on the ddPCR platform. In patients with
years on ART, an increase of the LTR:gag ratio is observed. This
can be explained by the clearance of gag-expressing viruses and/or
the clonal expansion of defective viruses, and indicates an
accumulation of viruses with deletions under ART.
In contrast, Eunok Lee (Westmead Institute for Medical Research,
Westmead, Australia) detected no accumulation of defective HIV
DNA sequences during ART by single genome/proviral sequencing
[30]. The group identified effector memory cells as the main
contributor to the increase in similar HIV DNA sequences caused
by proliferation in peripheral blood during therapy.
When considering the group of HIV controllers, data were
presented showing its heterogeneity as shown by HIV DNA levels
in those with a detectable VL (bHIC) increasing over time in
contrast to those with an undetectable VL (uHIC) with decreasing
levels over time. The former also have lower levels of CD8 T cell
activation [31]. These data may be influential in terms of ART
prescribing in this population.
The assessment of HIV integration site location and frequency in
latently infected CD4 T cells can help the understanding of viral
persistence. Jori Symons described a modified method for
integration site analysis that allows high-throughput workflow [32].
It was noticeable that viral integration occurred preferentially into
genes known to be upregulated in TCR-activated CD4 T cells.
Genevieve Martin (University of Oxford, UK) discussed the
expression of CD32+, a newly described marker of the viral
reservoir, on CD4T cells [33]. She confirmed the finding by Monsef
Benkirane‘s (Institute of Human Genetics: CNRS, France) group
in the symposium session ‘Advances in HIV Transmission and
Regulation of Replication’ (MOSY0204) of a substantial HIV DNA
enrichment in CD32 cells in patients 1 year after starting ART at
PHI This phenomenon is not only observed in PBMCs but also
in tonsillar tissue. The Benkirane group had previously suggested
that proviral integration upregulated CD32; however, there was
no difference found in its expression between HIV-infected
individuals and healthy controls (1.5% of CD4 T cells). Further
characterisation of these cells has shown that CD32 is co-expressed
with other HIV reservoir markers such as PD1, HLA-DR, Tim-3,
Tigit and CD2, and particularly on T cells with a differentiated
memory phenotype (TEM and TEMRA).
Comorbidities and immune activation
Maud Lemoine (Imperial College London, UK) presented the
METAFIB study results at the HIV and Liver Oral Abstract Session
[34]. In 468 HIV-monoinfected individuals, obesity and insulin
resistance were independent factors associated with significant
liver fibrosis (≥F2). Serum leptin and sCD163 levels were associated
with the degree of liver fibrosis.
Hugo Perazzo Pedroso Barbosa (Fundação Oswaldo Cruz, Brazil)
presented the PROSPEC-HIV study evaluating the risk factors
associated with liver fibrosis (LF) and steatosis using transient
elastography in HIV-monoinfected patients on ART [35]. In an age-
and gender-adjusted multivariate analysis, factors associated (OR,
95%CI) with LF were: age >45 years (2.91, 1.19–7.15; P=0.020),
CD4 T cell count <200 cells (5.00, 1.38–18.21; P=0.014) and type
2 diabetes (3.04, 0.97–9.55; P=0.056). Male gender (5.69,
2.68–12.04; P<0.001), dyslipidaemia (2.86, 1.46–5.60; P=0.002),
type 2 diabetes (6.00, 2.08–17.28; P=0.001), central obesity
(10.24, 4.11–25.50; P<0.001) and metabolic syndrome were
independently associated with liver steatosis by CAP. Longer ART
treatment duration, especially with zidovudine as a backbone, was
associated with steatosis, independently of metabolic factors.
The poster discussion session (MOPDB01) on ‘Comorbidities in
an Ageing Era’ opened with the results from the German HIV Heart
Study, an ongoing prospective multicentre trial that is being
conducted to analyse the incidence, prevalence and clinical course
of cardiovascular (CV) disorders in HIV-positive outpatients. It was
presented by Stefan Esser (University Hospital Essen, Germany)
[36]. The HIV-positive male subjects had an increased incidence
of CV events compared to the negative controls, despite a similar
Framingham risk score (FRS) at baseline, but a different smoking
status (P<0.0001), in contrast to HIV-positive females with a higher
FRS than controls but comparable rates of CV events. The
HIV-positive males had a higher mortality rate, risk of death or
of experiencing a CV event at a younger age than the general
population. The authors observed adjusted hazard ratios (aHR)
of 3.5 (95% CI 2.2–5.5) for CV events for male subjects in the
HIV HEART (HIVH) study in comparison to the Heinz Nixdorf
Recall (HNR) study that includes a sample from the general
population, for stroke of 1.8 (96% CI 0.8–3.9) for males and 2.2
(95% CI 0.1–42.9) for females. Overall survival in male and female
participants in the HIVH versus HNR had an hazard ratio of 3.9
(95% CI 2.5–6.1) and 1.7 (95%CI 0.2–12.3), respectively.
In a workshop on ‘Residual Disease and Immune Activation/
Inflammation on ART’ (MOWS03), Caroline Sabin (University
College London, UK) (MOWS0302) discussed the basic rules of
epidemiology in a time of abundance of studies on premature
ageing and earlier age for comorbidities in PLWH. She described
how the selection of a control group can affect our interpretation
of the impact of HIV on comorbidities and/or biomarkers. PLWH
have different characteristics compared to the general population,
which may drive apparent ageing rather than HIV itself. For
instance, cytomegalovirus (CMV) serostatus can be a major
confounding factor, driving immune activation and CD4/CD8 T
cell senescence, rather than HIV itself. In this context, age
advancement (biological age-derived using a set of 10 biomarkers
– chronological age) can be a variable refining the comparison
between PLWH and controls, decreasing misinterpretation of
studies and simplifying search for mechanisms.
Peter Hunt (University of California, San Francisco, USA) described
viral cofactors associated with immune ageing such as CMV and
HCV (MOWS0304). Cytomegalovirus elicits a massive immune
response even in asymptomatic HIV-negative individuals and may
plausibly contribute to CV and thromboembolic disease, HIV
reservoir persistence and microbial translocation. Furthermore, HCV
appears to increase the risk of type 2 diabetes, kidney disease
and osteoporotic fractures, with an unclear impact on coronary
artery disease surrogate markers and extrahepatic events after HCV
treatment with direct-acting antivirals (DAAs).
Roger Le Grand (Service Immunologie des Infections Virales et des
Maladies Auto-immunes [IMVA], France) provided a comprehensive
review of the impact of inflammation in disease progression in
non-human primate models (MOWS0305).
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Linda Wittkop (Bordeaux Population Health, France) presented
some heterogeneous results regarding the association between
inflammation markers and non-AIDS events (MOWS0306). She
described the complexity of the underlying mechanisms of
inflammation for each of the non-AIDS events, and the evolution
of markers on successful ART, which are not yet fully determined
from existing cohorts.
Olivier Lambotte, (Paris-Sud University Hospital, France) presented
interventions to reduce immune activation according to its different
causes (MOWS0307). Interventions on viral persistence, microbial
translocation, CD4 T cell depletion, interferon type I pathway,
metabolism, co-infections and lifestyle should be put into practice
and strategies should be combined in order to act on immune
activation. However, reduction of immune activation is inseparable
from that of HIV reservoirs and is a major objective in ‘HIV cure’
strategies aiming at improving the care of HIV-positive individuals.
The bridging session, ‘Microbiome’ (TUBS02), assembled
presentations of outstanding importance. Jacques Ravel (University
of Maryland School of Medicine, USA) described the vaginal
microbiota (TUBS0203). It can be quantitatively and qualitatively
different among ethnic groups, during infections (Lactobacillus
spp normally dominant), and over women‘s lifespans or during
menses. The intravaginal bacterial community state types may
contribute to variations in the diffusional barrier properties of the
cervico-vaginal mucus and influence the risk for the acquisition
of HIV and other STIs.
Jason Brenchley, (Laboratory of Parasitic Diseases, NIAID, NIH,
USA) discussed the microbiome in animal models (TUBS0204).
He showed studies providing evidence that the gastrointestinal
(GI) tract-resident microbes contribute to the exacerbation of
inflammation and SIV/HIV progression. It is currently unknown
to what extent dysbiosis may be responsible for susceptibility to
HIV infection or whether it is caused by HIV infection itself. The
microbiome dysbiosis does not influence untreated disease
progression.
Nichole Klatt (University of Washington, USA) presented evidence
from her latest study (CAPRISA-004) (TUBS0205). She showed
that the vaginal microbiota impact microbicide/PrEP efficacy and
HIV acquisition. Indeed, tenofovir is rapidly depleted by vaginosis-
associated bacteria because it is metabolised to adenine by
Gardnerella vaginalis more rapidly than target cells can take it up
for protection.
The Track B Oral Abstract Session described a series of different
comorbidities. Jessica Castilho (Vanderbilt University Medical
Center, USA) discussed the trends of non-communicable disease
(NCD) multimorbidity among adults initiating ARVs in the Coorte
Brasil, presenting two or more cumulative NCDs [37]. The NCD
incidence is increasing in this population and female sex is
independently associated with increased risk. Hyperlipidaemia,
diabetes and osteoporosis account for the majority of NCDs.
Matthew Freiberg (Vanderbilt University Medical Center, USA)
discussed whether HIV-infected people have an increased risk of
peripheral artery disease (PAD) compared to uninfected people
[38]. When analysing data on 92,287 VACS participants without
prevalent CV disease, he concluded that HIV infection is associated
with an increased risk of incident PAD even after adjustment for
traditional CV disease risk factors. Among HIV-infected veterans,
those with higher HIV VL and lower CD4 cell counts have the
highest PAD risk. It has an impact on mortality, which was greatest
among those with immunodeficiency or unsuppressed virus.
Dominique Costagliola (Sorbonne Universités, Paris, France)
presented an analysis from FHDH ANRS CO4 regarding the risk
of fractures in HIV-positive individuals, and the impact of exposure
to different ARVs [39]. It was a case–control study with individuals
enrolled while naive to ARV and no evidence of excess risk of
fracture was found following exposure to tenofovir or PIs.
Cumulative exposure to efavirenz was associated with a lower risk
of fractures.
Maartje Dijkstra (Public Health Service of Amsterdam, the
Netherlands) discussed erectile dysfunction among older HIV-
positive MSM [40]. HIV-1 status was independently associated
with decreased erectile function in those aged ≥45 years. This
higher prevalence of decreased sexual satisfaction and desire may
be explained by a high prevalence of depression, frailty and
age-related comorbidities.
Nithya Srinivas (University of North Carolina at Chapel Hill, USA)
studied the ARV concentration in the brain tissue and cerebrospinal
fluid (CSF) of uninfected and SHIV-infected rhesus macaques, in
relation to the concentration of drug transporters in brain tissue
[41]. Even if there was no difference in ARV concentrations
between different parts of the brain, tissue concentrations were
shown to be significantly higher than CSF for efavirenz,
emtricitabine and tenofovir. Drug concentrations in the CSF were
predictive of brain tissue concentrations only for EFV. Brain tissue
concentrations of EFV were four-fold higher in uninfected animals
compared to HIV-infected animals. The Breast Cancer Resistance
Protein (BCRP) protein (drug transporter) concentrations were
two-fold lower in uninfected animals than in infected ones. There
was a trend noted between increasing concentrations of BCRP
protein and lower efavirenz concentration in brain tissue.
Vaccines
Anthony Fauci (National Institutes of Health, USA) discussed the
relevance of an HIV vaccine for ending the HIV pandemic
(SUSA2202). Theoretically, HIV can be stopped without an HIV
vaccine; available drugs have improved over the last 30 years. There
are currently over 30 FDA-approved antiretroviral agents. Life
expectancy has dramatically improved since 1980 and additionally,
there is a strong focus on HIV prevention, namely treatment to
prevent infection of HIV-negative partners in discordant couples
and the availability of PrEP. There are no more excuses; we have
all the tools necessary to end the HIV pandemic. However, new
infections globally have only decreased by 2.3% annually and there
is a persistent important treatment gap. The ‘90-90-90’ targets
for 2020 are met in only a few countries, and globally only 44%
of HIV-infected people have viral suppression. Reaching the 2020
target is especially difficult when patients are living in rural areas
and dispersed. Furthermore, in the US over 1.2 million people are
at risk of HIV, but only 10% of them have access to PrEP. When
considering vaccine development there are two approaches that
can be considered. First, in a classical approach a vaccine candidate
is tested to identify if it evokes an immune response, which can
be protective (e.g. modified RV144 prime-boosted in the HVTN702
trial). A second approach is to assume a correlate of immunity and
design a vaccine to induce this correlate. In this strategy, bNAbs
have been the focus. For an HIV vaccine to have a strong impact
a 50–60% efficacy rate in combination with prevention and
treatment would suffice to end the epidemic.
During the symposium session, ‘Translational Vaccinology’
(MOSY04), Hanneke Schuitemaker (Janssen Vaccines and
Prevention, the Netherlands) presented data from the APPROACH
early clinical study aimed at developing a prophylactic vaccine.
An immunogen should offer protection against all HIV-1 clades
through a heterologous prime-boost regimen (double prime at
month 0 and 3 and double boost at month 6 and 12)(MOSY0403).
APPROACH is a multicentre, randomised, parallel-group, placebo-
controlled, double-blind clinical trial in healthy HIV-uninfected
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adults. Safety and immunological results of the APPROACH and
TRAVERSE studies will inform the decision to proceed to a Phase
2b proof-of-concept study. In parallel preclinical studies the
Ad26/Ad26+gp140 HIV vaccine regimen provided significant
protection (94% per-exposure risk reduction) against intrarectal
SHIV challenges in NHP. All vaccine regimens were 100%
immunogenic after the third immunisation in terms of the humoral
(total IgG against gp140 ENV Clade C by ELISA), ADCP
(functionality of antibodies via antibody-dependent cellular
phagocytosis) and cellular (ENV PTE peptide pool by ELISPOT)
responses and also displayed a very favourable safety profile. There
was a clear contribution of the gp140 boost and dose in all types
of responses. The number of responders was maintained after the
fourth vaccination. The ADCP, magnitude of response and Env
boost criteria are considered supportive for the lead regimen
(Ad26/Ad26+gp140 high dose) and results of the TRAVERSE study
are close (end of 2017) in order to proceed with the proof-of-
concept study that will consist of a multicentre, randomised, parallel
group, placebo-controlled, double-blind clinical trial targeting
sexually active HIV-1-uninfected women (born female, age 18–35
years) in five African countries.
Hepatitis C virus (HCV)
Chronic HCV disease is associated with substantial morbidity and
mortality worldwide. It disproportionately affects PLWH,
complicating the management of HIV and impacts on the ART
response. The use of DAAs is associated with >95% sustained
virological response (SVR) rate. DAAs have also demonstrated
reasonable safety profiles. The availability of effective HCV
treatment, with high cure rates for all genotypes, offers
unprecedented opportunities. However, barriers to achieve a cure
include high treatment costs, health services delivery issues,
insufficient HCV screening programmes and limited HCV prevalence
data.
French investigators Salmon et al. presented results regarding VF
with DAA combinations in HIV/HCV-co-infected patients from the
ANRS CO13 HEPAVIH cohort [42]. The rate of VF in this cohort
was low and involved 32 of 619 HCV/HIV-co-infected individuals
(5.2%, 95% CI 3.6–7.2). The majority were relapsers (78%)
followed by non-responders (9%) and one breakthrough. People
with VF had a lower median CD4 cell count (505 vs 614 cells/mm3,
P=0.008) and with a larger proportion with an undetectable HIV
VL (75% vs 87%, P=0.0606) and a lower platelet count (141 vs
172; P=0.0669). Presence of cirrhosis or type of DAA regimen
did not affect the probability of VF. Using a marginal structural
model and after adjustment for ribavirin use, age, sex, cirrhosis,
HCV genotype, and CD4 cell count, investigators identified two
independent predictors: pretreatment with a non-DAA regimen
almost tripled the chance of failure (odds ratio [OR] 2.8, 95% CI
1.2–6.2, P=0.004), and DAA treatment for 24 weeks versus 12
weeks lowered the chance of failure by 80% (OR 0.2, 95% CI
0.1–0.6, P=0.01). Age, gender, HCV genotype, HIV load, and CD4
cell count did not predict VF in this analysis. Some VF could also
be due to suboptimal adherence as suggested by: (1) suboptimal
DAA concentrations in 4/10 people with VF; and (2) a higher rate
of detectable HIV RNA among people with VF in a separate logistic
regression analysis (OR 2.1, 95% CI 0.9–5.1, P=0.11). The
emergence of resistance-associated mutations (RAS) was frequent
and varied according to the DAA class: 2/2 in the NS3 failure group
and 6/12 in the NS5A failure group.
In the same cohort, investigators assessed the prevalence of
overweight/obesity after SVR [43]. Cohort participants who
completed at least one self-administered questionnaire during the
2005–2014 follow-up period were eligible for this analysis. Mixed
logistic regression models were used to pinpoint predictors of
overweight/obesity. Of the 1046 people analysed, 18.3% were
overweight or obese at the start of follow-up. Ex-smokers and
non-smokers presented a higher prevalence (29.4% and 29.5%,
respectively) of overweight/obesity than current smokers (14.5%;
P=0.0001). One-third of participants (35.2%) reported hazardous
alcohol consumption, and half (49.7%) used cannabis. Cannabis
users had a lower overweight/obesity prevalence than non-users
(9.7% vs 23.8%, P<0.0001). After 5 years of follow-up, 27% were
overweight or obese. In the multivariate analysis, HCV clearance
did not significantly affect odds of overweight/obesity but a longer
time after clearance boosted odds of overweight/obesity by about
75% (adjusted odds ratio [aOR] 1.74, 95% CI: 1.003–3.03,
P=0.049). Other variables that independently lowered odds of HCV
clearance were female gender (aOR 0.43, 95% CI 0.25–0.71,
P=0.001), each year of ART at the first visit (aOR 0.91, 95% CI
0.87–0.96, P=0.0003), and cannabis use (aOR 0.22, 95% CI
0.08–0.61, P=0.005).
Nadine Kronfli (University Health Centre, Montreal, Canada)
presented results from the Canadian HIV-HCV Co-infection Cohort
(CCC) that looked into cause-specific mortality in co-infected
people and changes in cause-specific mortality before and after
increased use of HCV therapy in this group [44]. Investigators
analysed 1477 people with an available date of birth and follow-up
in the study period (median 4.1 years). Most participants (84%)
were on ART, 64% had an undetectable HIV load, and 81% had
no HCV therapy experience at baseline. During follow-up, 203
people (14%) died (death rate of 30.5 per 1000 person-years).
People who died had a median age at death of 47 years, were
more likely to report active IDU and current smoking, had a lower
median CD4 cell count, were less likely to have an undetectable
HIV load, had longer HCV infection, were more likely to be HCV
treatment-naive at baseline, had worse fibrosis, and were more
likely to have a prior end-stage liver disease (ESLD) diagnosis.
ESLD accounted for 20% of deaths. Risk of death from ESLD fell
over time in this analysis (HR 0.65) but not significantly (95%
CI 0.28–1.5). Overall, death due to ESLD decreased only in people
50–80 years. ESLD deaths were about five-fold more likely with
an AST to platelet ratio index (APRI) above 1.5 and with HCV RNA
positivity, and about three-fold more likely with a CD4 cell count
below 350 cells/mm3. The all-cause death risk was higher in people
positive for HCV RNA at the last visit. Death due to ESLD was
common and did not decrease over time in people with poorly
controlled HIV and HCV, especially with detectable HCV RNA. Thus,
researchers suggested that the mortality benefit of DAA therapy
will be concentrated among those with advanced fibrosis and
efforts to expand treatment should prioritise this group.
Karine Lacombe (Université Pierre et Marie Curie, France, Paris)
described the results from the Phase 3 Expedition-2 international
study using co-formulated glecaprevir/pibrentasvir once daily in
HIV-HCV-co-infected patients using an 8- or 12-week treatment
duration in non-cirrhotic and cirrhotic patients, respectively [45].
The treatment was well tolerated and highly efficacious with a
cure rate of 98% in a predominantly genotype 1 (including 1a)
population. Glecaprevir is an HCV protease inhibitor and
pibrentasvir an NS5A inhibitor. Both are pangenotypic. Most
patients were on an integrase inhibitor-based ART. This
combination could be the first 8-week pangenotypic treatment
option for HCV-HIV co-infected patients without cirrhosis.
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